Medication info
Megalosuvastatin 10 mg (Rosuvastatin Calcium)

Megalosuvastatin 10 mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
L&C Bio Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets per bottle
Approval status
Active

MFDS item code 201804898 · Approved 2018.12.04 · Insurance code 060500140

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and reduction of cardiovascular disease risk
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams per day. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on administration of doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
L&C Bio Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and reduction of cardiovascular disease risk

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • risk factors for coronary artery disease
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This drug is primarily used as an adjunct in patients with hypercholesterolemia and mixed dyslipidemia where dietary measures and exercise are insufficient. It particularly helps lower cholesterol levels in patients with familial hypercholesterolemia and delays the progression of atherosclerosis. It is also used in pediatric patients aged 10 to 17 years with high LDL cholesterol levels that cannot be adequately controlled with diet alone. This drug also plays an adjunct role in the treatment of patients with dysbetalipoproteinemia. Additionally, it has effects in reducing the risks of stroke, myocardial infarction, and vascular interventions in middle-aged or older patients with cardiovascular disease risk factors. Overall, it is used to lower cholesterol levels and improve cardiovascular health.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams per day. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on administration of doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years of age: Safety and efficacy have not been established.

Precautions

This drug should not be used in certain patients. For example, it should not be administered to patients who are allergic to any components of this drug, patients with severe liver dysfunction, those with muscle diseases, or patients with significantly impaired kidney function. Women who are pregnant or breastfeeding, as well as fertile women who do not use adequate contraception, should not use this drug. Furthermore, high doses are prohibited in patients at high risk of muscle disease. This drug should be used cautiously in patients who consume alcohol excessively or have a history of liver disease, and it is advisable to repeat liver function tests before and during treatment. If symptoms such as muscle pain or weakness occur, patients should immediately inform their doctor and undergo necessary examinations. In particular, if muscle enzyme levels rise significantly, the drug should be discontinued, and it may be reconsidered for re-administration at an appropriate dose once symptoms improve. This drug may elevate blood glucose levels in some patients; therefore, patients at risk of diabetes should vigilantly manage their blood sugar. Additionally, this drug contains lactose, and patients with lactose intolerance should not take it. There may be interactions with this drug and other medications, so if there are any currently taken medications, patients must inform their doctor or pharmacist. In particular, co-administration with certain antiviral drugs, immunosuppressants, and fibrate drugs may increase the risk of muscle-related side effects. Pregnant or breastfeeding women should not use this drug, and women who may become pregnant should use appropriate contraception. Caution is necessary as this drug may pose a risk to the fetus during pregnancy. In case of overdose, there is no specific antidote, so symptomatic management should be provided while monitoring liver function and muscle enzyme levels. This drug may cause symptoms such as dizziness; therefore, caution is needed when driving or operating machinery. Finally, if severe skin rashes or allergic reactions occur while using this drug, it should be promptly discontinued and medical consultation sought.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculomotor weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, drug rash resembling psoriasis, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to prevent exposure to air or moisture. The storage temperature should ideally be maintained at room temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.